Mankind Pharma sets a new benchmark, launching 120 Premium DMF quality

Jun 15, 2023

29-08-2023Comments (0)Print

11-08-2023

17-07-2023

08-06-2023

08-02-2022

22-08-2023

14-08-2023

08-08-2023

Shares of Indian generic drugmaker Mankind Pharma (BSE: 543904) edged up 1% today, after it boasted a significant stride with the introduction of 120 DMF (Drug Master File) Quality Medicines in the Indian market.

Committed to delivering exceptional healthcare solutions at affordable rates, Mankind Pharma's initiative aims to ensure universal access to medicines of international calibre, the company noted.

India stands as a global leader in offering…

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

• All the news that moves the needle in pharma and biotech.• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. • Receive The Pharma Letter daily news bulletin, free forever.

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.• Daily roundup of key events in pharma and biotech.• Monthly in-depth briefings on Boardroom appointments and M&A news.• Choose from a cost-effective annual package or a flexible monthly subscription.

All therapy areasFocus OnGenericsIndiaMarkets & MarketingProduct LaunchRegulation